Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07467629) titled 'QLS5212 for Participants With Advanced Solid Tumors' on March 8.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Qilu Pharmaceutical Co., Ltd.

Condition: Solid Tumor Cancer

Intervention: Drug: QLS5212

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: April 30, 2026

Target Sample Size: 100

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07467629

Published by HT Digital Content Services with permission from Hea...